Huadong Medicine Co., Ltd.
Semi-Annual Report 2022
August 2022
Section I. Important Declaration, Contents and Definitions
The Board of Directors, Board of Supervisors, directors, supervisors
and senior management of Huadong Medicine Co., Ltd. (hereinafter
referred to as the “Company”) hereby guarantee that the information
presented in this half yearreport is authentic, accurate and complete and
free of any false records, misleading statements or material omissions,
and shall undertake individual and joint legal liabilities.
Lv Liang, the Company’s legal representative and the officer in
charge of accounting, and Qiu Renbo, head of accounting department
(accounting supervisor) hereby declare and guarantee that the financial
statements in this half year report are authentic, accurate and complete.
All directors have attended the Board of Directors meeting to review
this half year report.
The future plans, development strategies and other forward-looking
statements in this half year report shall not be considered as substantial
commitment of the Company to investor. Investors and related parties
should maintain sufficient risk awareness, and should understand the
difference between plans, forecasts and promises.
The risks the Company faces in operation including industry policy
and market operation risk, new drug R&D risk, exchange rate
fluctuation risk and goodwill impairment risk , etc. For details, refer to
“X. Risks and Countermeasures” in“Section III. Discussion andAnalysis
of the Management”. We thank all investors for paying attention to the
Company’s operations, and we hope that you can be aware of investment
risks.
The company does not plan to distribute cash dividends, no bonus
share will be issued; and no capital reserve will be converted to increase
the share capital.
Accordingto“StockListingRulesoftheShenzhenStockExchange”,
if listed companies have both Chinese orother language version of public
notice, they should ensure the content of both versions are the same. In
the case of discrepancy, the original version in Chinese shall prevail.
Contents
Section I. Important Declaration, Contents and Definitions ...... 2
Contents...... 3
Definitions ...... 5
Section II. Company Profile and Key Financial Indicators ...... 7
Section III. Discussion andAnalysis of the Management......10
Section IV. Corporate Governance ......57
Section V. Environmental and Social Responsibility ......60
Section VI. Important Matters......72
Section VII. Share Change and Shareholders ......92
Section VIII. Preferred Shares ......100
Section IX. Information about Bonds ......101
Section X. Financial Report......102
Contents of Reference File
I. Financial statements signed and stamped by the legal representative, the person in
charge of accounting work and the head of accounting institution (accounting manager).
II. The original of all Company’s documents publicly disclosed in the press designated by
CSRC during the reporting period and the original of announcements.
Definitions
Term refers to Definition
CSRC refers to China Securities Regulatory Commission
SSE refers to Shenzhen Stock Exchange
Huadong Medicine/the Company/our Company refers to Huadong Medicine Co., Ltd.
CGE refers to China Grand Enterprises, Inc.
Huadong Medicine Group refers to Hangzhou Huadong Medicine Group Co., Ltd.
Zhongmei Huadong refers to Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Jiangdong Company refers to Hangzhou Zhongmei Huadong Pharmaceutical Jiangdong Co., Ltd.
Jiuyang Bio refers to Jiangsu Jiuyang Biopharm Co., Ltd.
Xi’an Bohua refers to Huadong Medicine (Xi’an) Bohua Pharmaceutical Co., Ltd.
Jiuyuan Gene refers to Hangzhou Jiuyuan Gene Engineering Co., Ltd.
Doer Biologics refers to Zhejiang Doer Biologics Co., Ltd.
Huadong Ningbo Company refers to Huadong Ningbo Medicine Co., Ltd.
Chongqing Peg-Bio refers to Chongqing Peg-Bio Biopharm Co., Ltd.
Qyuns Therapeutics refers to Qyuns Therapeutics Co., Ltd.
Nuoling Bio refers to Nuoling Biomedical technology (Beijing) Co., Ltd.
Grand Chanrong refers to Shanghai Grand Industrial and Financial Investment Management
Co., Ltd.
Hangzhou Gaotou refers to Hangzhou Hi-Tech Venture Capital Management Co., Ltd.
Grand Huachuang refers to Beijing Grand Huachuang Investment Co., Ltd.
Hangzhou Heda
查看PDF原文
